EU approval for Eisai kidney cancer treatment
pharmafile | September 15, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Afinitor, Eisai, Kisplyx, Lenvima, everolimus
The European Commission has approved the use of Eisai’s Kisplyx (lenvatinib) for the treatment of renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF) targeted therapy, when used in combination with everolimus (Novartis’ Afinitor).
This marks the second region the treatment has been licensed in for tackling the advanced kidney cancer after the US. The drug is an oral molecular tri-specific targeted therapy with potent selectivity, and already available in Europe for treatment of progressive, locally advanced or metastatic differentiated (papillary, follicular, Hürthle cell) thyroid carcinoma, refractory to radioactive iodine under the tradename Lenvima.
The decision was based on results of a Phase II study that found that patients treated with lenvatinib plus everolimus demonstrated a significant extension in the study’s primary endpoint of progression free survival (PFS) compared to those treated with everolimus alone. Additionally, updated median overall survival was 25.5 months in the lenvatinib plus everolimus group compared with 15.4 months in the everolimus alone group.
Renal cell carcinoma affects approximately 338,000 worldwide, accounting for more than 90% of all malignancies of the kidney.
Matt Fellows
Related Content
Eisai shares new data for Leqembi for Alzheimer’s treatment
Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL …
FDA grants Alzheimer’s disease drug Leqembi full approval
Japanese pharmaceutical company Eisai and US-based biotechnology company Biogen have announced that the US Food …
Eisai and Wren Therapeutics join forces to tackle neurodegenerative synucleinopathies
Eisai has forged an exclusive research partnership with Wren Therapeutics to develop new approaches in …